Market Overview

Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication

Related LGND
Milestone Payment for Ligand Pharma - Analyst Blog
Bright Outlook at Ligand - Analyst Blog
Related GSK
Glaxo Looking into Misconduct Charges - Analyst Blog
Pharmaceutical Stocks For Income, Value And Growth Investors
Amgen, GSK End Marketing Pact for Osteoporosis Drug (Fox Business)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. PROMACTA in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.

Posted-In: News FDA

 

Most Popular

Related Articles (LGND + GSK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free